RAPT Therapeutics Inc
RAPT57.690USD
+0.010+0.02%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
972.39M시가총액
손실P/E TTM
자세한 내용은 RAPT Therapeutics Inc 회사
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
RAPT Therapeutics Inc 정보
종목 코드 RAPT
회사 이름RAPT Therapeutics Inc
상장일Oct 31, 2019
CEOWong (Brian)
직원 수68
유형Ordinary Share
회계 연도 종료Oct 31
주소561 Eccles Ave
도시SOUTH SAN FRANCISCO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94080
전화16504899000
웹사이트https://rapt.com/
종목 코드 RAPT
상장일Oct 31, 2019
CEOWong (Brian)
RAPT Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
4.96K
+4956.00%
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
4.96K
+4956.00%
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
4.96K
+4956.00%
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
4.96K
+4956.00%
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
4.96K
+4956.00%
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
4.96K
+4956.00%
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
4.96K
+4956.00%
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
4.96K
+4956.00%
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Mon, Nov 17
마지막 업데이트: Mon, Nov 17
주주
주주 유형
주주
주주
비율
Medicxi Ventures (UK) LLP
9.65%
Forbion Capital Partners
6.33%
TCG Crossover Management, LLC
5.65%
Foresite Capital Management, LLC
5.40%
RTW Investments L.P.
5.08%
기타
67.90%
주주
주주
비율
Medicxi Ventures (UK) LLP
9.65%
Forbion Capital Partners
6.33%
TCG Crossover Management, LLC
5.65%
Foresite Capital Management, LLC
5.40%
RTW Investments L.P.
5.08%
기타
67.90%
주주 유형
주주
비율
Investment Advisor
17.25%
Venture Capital
16.59%
Hedge Fund
11.52%
Private Equity
9.78%
Investment Advisor/Hedge Fund
9.36%
Individual Investor
0.34%
Research Firm
0.31%
Sovereign Wealth Fund
0.04%
기타
34.79%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
289
18.74M
64.73%
+113.56K
2025Q3
290
16.78M
61.62%
-1.23M
2025Q2
295
16.40M
99.19%
-1.13M
2025Q1
309
29.14M
109.47%
+11.54M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Medicxi Ventures (UK) LLP
2.79M
10.08%
--
--
Sep 30, 2025
Forbion Capital Partners
1.83M
6.62%
+1.49M
+432.58%
Oct 23, 2025
TCG Crossover Management, LLC
1.64M
5.9%
--
--
Sep 30, 2025
Foresite Capital Management, LLC
1.56M
5.64%
--
--
Sep 30, 2025
RTW Investments L.P.
1.47M
5.31%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
696.19K
2.51%
-183.86K
-20.89%
Sep 30, 2025
OrbiMed Advisors, LLC
1.09M
3.92%
-555.29K
-33.82%
Sep 30, 2025
Boone Capital Management LLC
782.46K
2.82%
+782.46K
--
Sep 30, 2025
Deep Track Capital LP
751.42K
2.71%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
623.28K
2.25%
-328.33K
-34.50%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
Invesco Dorsey Wright SmallCap Momentum ETF
0.56%
Avantis US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
Blueprint Chesapeake Multi-Asset Trend ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 3000 ETF
0%
Pacer WealthShield ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
더 보기
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.56%
Avantis US Small Cap Equity ETF
비율0.02%
Invesco RAFI US 1500 Small-Mid ETF
비율0.01%
Schwab U.S. Broad Market ETF
비율0%
Blueprint Chesapeake Multi-Asset Trend ETF
비율0%
Virtus LifeSci Biotech Clinical Trials ETF
비율0%
DFA Dimensional US Core Equity Market ETF
비율0%
iShares Russell 3000 ETF
비율0%
Pacer WealthShield ETF
비율0%
T Rowe Price Small-Mid Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Jun 13, 2025
Merger
8→1
날짜
배당락일
유형
비율
Jun 13, 2025
Merger
8→1
